Rep. Lloyd Doggett Purchases Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lloyd Doggett (D-Texas) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on March 4th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 3/27/2025.
• Purchased $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 3/12/2025.
• Purchased $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 2/18/2025.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $2.93 during trading hours on Friday, hitting $151.62. 9,940,249 shares of the company's stock traded hands, compared to its average volume of 7,949,830. The company's fifty day simple moving average is $159.40 and its two-hundred day simple moving average is $155.21. The company has a market cap of $365.39 billion, a price-to-earnings ratio of 22.80, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a report on Wednesday. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $171.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after acquiring an additional 1,561,036 shares in the last quarter. Northern Trust Corp increased its stake in shares of Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $4,390,037,000. Finally, Wellington Management Group LLP boosted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas' 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas' 37th Congressional District. He declared candidacy for the 2026 election. Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett's career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.